Medical sector’s Kalvista Pharmaceuticals’s (NASDAQ:KALV) Buy rating Reiterated by HC Wainwright

0
47
stock_market_daily_information
Business or finance concept : Asia Pacific stock market data and candle stick graph chart on monitor

Kalvista Pharmaceuticals (NASDAQ:KALV)‘s stock had its Buy rating Reiterated by analysts at HC Wainwright in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 231.5M and a beta of 2.49.  Kalvista Pharmaceuticals has a twelve month low $5.61 of  and a twelve month high of $20.57.

Shares of Kalvista Pharmaceuticals traded up $0.85 on Thursday, reaching $12.97. 175204 shares of the stock traded hands, compared to its average volume of 163583. Shares of Kalvista Pharmaceuticals at end of the day on Thursday were at $12.97. The firm’s 50 day moving average is $$11.11 and its 200 day moving average is $12.42.Kalvista Pharmaceuticals  has a 12 month low of $12.13 and a 12 month high of $20.57. While on yearly highs and lows, Kalvista Pharmaceuticals’s today has traded high as $13.11 and has touched $12.13 on the downward trend. See More Analyst Rating at: RATING

Kalvista Pharmaceuticals (NASDAQ:KALV) Moving Average Technical Analysis

5 day Moving Average is $12.46 And 5 day price change is $1.16 (9.82%)  with average volume for 5 day average is 228,860. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $11.38 and 20 day price change is $1.27 (10.85%) and average 20 day moving volume is 217,825. 50 day moving average is $11.11  and 50 day price change is $1.73 ( 15.39%)  and with average volume for 50 days is : 142,514. 200 day moving average is $12.42  and 200 day price change is -$1.70 (-11.59%)  and with average volume for 200 days is : 146,745.

See More Analyst Rating at: RATING

Kalvista Pharmaceuticals Earnings and What to expect: 

Kalvista Pharmaceuticals last released its quarterly earnings data on July 1st, 2020. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.28. The firm had revenue of $3.82 million for the quarter, compared to analyst estimates of $2.05 million. Kalvista Pharmaceuticals has generated ($1.64) earnings per share over the last year. Kalvista Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, September 14th, 2020 based off prior year’s report dates.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 21.60%
  • On 12/16/2019 Insider Christopher Yea Sell 3,010 at average share price of $17.05 which equates to $51,320.50 in money value.
  • On 12/16/2019 CEO Thomas Andrew Crockett Sell 5,400 at average price of  $17.06 with total value of : Not Data Available
  • On 12/13/2019 Insider Christopher Yea Sell 1,500 at average price of  $17.05 with total value of : $25,575.00

What other brokers have to say about Kalvista Pharmaceuticals :

  • 7/2/2020 – Minerva Neurosciences had its “buy” rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. (View)
  • 7/2/2020 – Neovasc had its “buy” rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock. (View)
  • 7/2/2020 – Provention Bio had its “buy” rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock. (View)
  • 7/2/2020 – CAN-FITE BIOPHA/S had its “buy” rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock. (View)

Other firm’s rating by HC Wainwright:

See More Analyst Rating at: RATING